Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John H Stone, M.D.

Co-Author

This page shows the publications co-authored by John Stone and Eli Miloslavsky.
Connection Strength

4.463
  1. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial. Semin Arthritis Rheum. 2018 10; 48(2):288-292.
    View in: PubMed
    Score: 0.768
  2. Case 14-2017: A Man with Pain and Swelling of the Left Calf and a Purpuric Rash. N Engl J Med. 2017 08 10; 377(6):601.
    View in: PubMed
    Score: 0.743
  3. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis Rheumatol. 2016 12; 68(12):2945-2952.
    View in: PubMed
    Score: 0.708
  4. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017 Mar; 76(3):543-546.
    View in: PubMed
    Score: 0.692
  5. Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2017 07; 69(7):1004-1010.
    View in: PubMed
    Score: 0.184
  6. Case 14-2017 - A 20-Year-Old Man with Pain and Swelling of the Left Calf and a Purpuric Rash N Engl J Med. 2017 05 11; 376(19):1868-1877.
    View in: PubMed
    Score: 0.183
  7. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol. 2015 Jun; 67(6):1629-36.
    View in: PubMed
    Score: 0.160
  8. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2015 Feb; 67(2):535-44.
    View in: PubMed
    Score: 0.156
  9. Challenging mimickers of primary systemic vasculitis. Rheum Dis Clin North Am. 2015; 41(1):141-60, ix.
    View in: PubMed
    Score: 0.155
  10. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2014 Nov; 66(11):3151-9.
    View in: PubMed
    Score: 0.153
  11. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013 Sep; 65(9):2441-9.
    View in: PubMed
    Score: 0.141
  12. Reply: To PMID 22736240. Arthritis Rheum. 2013 Aug; 65(8):2217-8.
    View in: PubMed
    Score: 0.141
  13. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012 Nov; 64(11):1720-9.
    View in: PubMed
    Score: 0.133
  14. Topic modeling to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A proof of concept study. Semin Arthritis Rheum. 2021 02; 51(1):150-157.
    View in: PubMed
    Score: 0.059
  15. Nationwide Trends in Hospitalizations and In-Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). Arthritis Care Res (Hoboken). 2017 06; 69(6):915-921.
    View in: PubMed
    Score: 0.046
  16. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016 Jun; 75(6):1166-9.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.